Tirzepatide · complete guide
Microdose tirzepatide: complete guide
Definitions, approved-product trials, evidence, risks, and cost for microdose tirzepatide.
This is the complete guide to microdose tirzepatide: what the term means, how it relates to approved tirzepatide products and their trials, what the evidence supports, the risks, the cost drivers, and what remains unknown. Tirzepatide is a dual GIP and GLP-1 receptor agonist — a different mechanism from semaglutide. Its weight-management evidence comes from the SURMOUNT program, including the SURMOUNT-4 withdrawal trial and the SURMOUNT-MAINTAIN reduced-dose maintenance design. Compounded tirzepatide is not FDA approved.
What microdose tirzepatide means
'Microdose tirzepatide' has no single clinical definition. Providers apply it to a range of below-maintenance approaches, so the milligrams behind two 'tirzepatide microdose' plans can differ widely. The honest starting point is to ask a provider exactly what dose, concentration, and form they mean.
Approved tirzepatide products & trials
Tirzepatide is the active ingredient in Zepbound and Mounjaro, both injectable. There is no FDA-approved oral tirzepatide of any kind, which makes any compounded 'oral tirzepatide' claim entirely outside approved-product evidence.
Since no oral tirzepatide is approved, a compounded oral or sublingual tirzepatide has no approved counterpart to borrow credibility from; absorption and effect are unestablished.
- SURMOUNT-4: continued tirzepatide vs placebo after a lead-in — regain after withdrawal.
- SURMOUNT-MAINTAIN: a 5 mg reduced maintenance dose vs maximum tolerated dose and placebo.
What the evidence shows
- Tirzepatide's dose-response is established for the approved product.
- SURMOUNT-MAINTAIN supports a specific 5 mg reduced maintenance dose; SURMOUNT-4 shows regain after withdrawal.
What the evidence does not show
- That a sub-therapeutic 'tirzepatide microdose' reproduces trial weight loss.
- That any oral tirzepatide is approved or evidence-backed.
Risks
The main risks are dosing errors from units-vs-milligrams confusion when a compounded tirzepatide concentration changes, unproven absorption for oral/sublingual forms, and the false assumption that 'less' is automatically safer or equally effective. Compounded tirzepatide raises the same ingredient-identity and pharmacy-verification questions as any compounded injectable, without an approved oral form to anchor expectations.
Cost
Compare microdose tirzepatide programs on effective monthly cost, not headline prices — see the tirzepatide cost page and the true-cost calculator.
Frequently asked questions
Is microdose tirzepatide FDA approved?
No. There is no approved 'tirzepatide microdose'; compounded low-dose tirzepatide is not FDA approved.
Does microdose tirzepatide work for weight loss?
Unproven. The weight-loss evidence is for approved tirzepatide at studied doses, not a deliberate microdose.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.